Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein - An analysis

Abstract

This review was written to critically analyze results from the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) study. Results were analyzed with reference to known processes of over nutrition, obesity, and inflammation, as described in the literature. JUPITER was a poorly designed study that contained no true control group and was terminated prematurely. Moreover, the study group was not apparently healthy, as suggested by the authors, but fell into the category largely of high risk for coronary disease. As a result, there was no true control group for comparison and so there is little or no evidence that measurement of C-reactive protein (CRP) is diagnostically useful in most persons. Although the results suggest that statin treatment could be promising for such a group of high-risk individuals, this remains unproven as a result of premature termination, and weight control and exercise that reduces true risk factors remain the main treatment in such persons. ©2009 Clinical Ligand Assay Society. All rights reserved.